56 Result(s)
within
Article
Victor L. Villemagne
-
Article
Intravenous Nicotine Reduces Cerebral Glucose Metabolism: A Preliminary Study
Nicotine is self-administered by smoking tobacco products, and enhances positive mood (at least in smokers). Since most drugs of abuse decrease regional cerebral metabolic rate(s) for glucose (rCMRglc) in huma...
-
Article
The ART of Loss: Aβ Imaging in the Evaluation of Alzheimer’s Disease and other Dementias
Molecular neuroimaging based on annihilation radiation tomographic (ART) techniques such as positron emission tomography (PET), in conjunction with related biomarkers in plasma and cerebrospinal fluid (CSF), a...
-
Article
Amyloid Imaging in Alzheimer’s Disease and Other Dementias
With the advent of new therapeutic strategies aimed at reducing β-amyloid (Aβ) burden in the brain to potentially prevent or delay functional and irreversible cognitive loss, there is increased interest in dev...
-
Article
Open AccessAβ Imaging: feasible, pertinent, and vital to progress in Alzheimer’s disease
-
Article
Comparison of 11C-PiB and 18F-florbetaben for Aβ imaging in ageing and Alzheimer’s disease
Amyloid imaging with 18F-labelled radiotracers will allow widespread use of this technique, facilitating research, diagnosis and therapeutic development for Alzheimer’s disease (AD). The purpose of this analysis ...
-
Article
Open Access18F-florbetaben Aβ imaging in mild cognitive impairment
18F-florbetaben and positron emission tomography were used to examine the relationships between β-amyloid (Aβ) deposition, cognition, hippocampal volume, and white matter hyperintensities in mild cognitive impai....
-
Article
Oligomers, fact or artefact? SDS-PAGE induces dimerization of β-amyloid in human brain samples
The formation of low-order oligomers of β-amyloid (Aβ) within the brain is widely believed to be a central component of Alzheimer’s disease (AD) pathogenesis. However, despite advances in high-throughput and h...
-
Article
Open AccessIn vivo TSPO imaging in patients with multiple sclerosis: a brain PET study with [18F]FEDAA1106
The activation of microglia, in general, and the upregulation of the translocator protein (18 kDa) (TSPO) system, in particular, are key features of neuroinflammation, of which the in vivo visualization and quant...
-
Article
Open AccessAssessing THK523 selectivity for tau deposits in Alzheimer’s disease and non–Alzheimer’s disease tauopathies
The introduction of tau imaging agents such as 18F-THK523 offers new hope for the in vivo assessment of tau deposition in tauopathies such as Alzheimer’s disease (AD), where preliminary 18F-THK523-PET studies hav...
-
Article
In vivo evaluation of a novel tau imaging tracer for Alzheimer’s disease
Diagnosis of tauopathies such as Alzheimer’s disease (AD) still relies on post-mortem examination of the human brain. A non-invasive method of determining brain tau burden in vivo would allow a better understa...
-
Article
Do current therapeutic anti-Aβ antibodies for Alzheimer’s disease engage the target?
Reducing amyloid-β peptide (Aβ) burden at the pre-symptomatic stages of Alzheimer’s disease (AD) is currently the advocated clinical strategy for treating this disease. The most developed method for targeting ...
-
Article
Open AccessImago Mundi, Imago AD, Imago ADNI
Since the launch in 2003 of the Alzheimer’s Disease Neuroimaging Initiative (ADNI) in the USA, ever growing, similarly oriented consortia have been organized and assembled around the world. The various accompl...
-
Article
Anti-Aβ antibody target engagement: a response to Siemers et al.
-
Article
The landscape of ageing—insights from AD imaging markers
The knowledge of imaging and fluid biomarkers gained from longitudinal observational studies of Alzheimer disease has recently been translated to a cross-sectional study of randomly selected, cognitively unimp...
-
Article
Suspected non-Alzheimer disease pathophysiology — concept and controversy
Suspected non-Alzheimer disease pathophysiology (SNAP) is a biomarker-based concept that applies to individuals with normal levels of amyloid-β biomarkers in the brain, but in whom biomarkers of neurodegenerat...
-
Article
Innate phagocytosis by peripheral blood monocytes is altered in Alzheimer’s disease
Sporadic Alzheimer’s disease (AD) is characterised by the deposition and accumulation of specific protein aggregates. Failure of clearance could underlie this process, and recent genetic association studies po...
-
Article
Performance on the Cogstate Brief Battery Is Related to Amyloid Levels and Hippocampal Volume in Very Mild Dementia
In a group of older adults with very mild dementia, we aimed to characterize the nature and magnitude of cognitive decline as measured by the Cogstate Brief Battery, in relation to Aβ levels and hippocampal vo...
-
Article
A Conceptualization of the Utility of Subjective Cognitive Decline in Clinical Trials of Preclinical Alzheimer’s Disease
This commentary outlines a conceptual model for subjective cognitive decline (SCD) in relation to Alzheimer’s disease (AD) biomarkers in the preclinical stages of disease and a framework for effectively utiliz...
-
Article
Open AccessA ‘Disease Severity Index’ to identify individuals with Subjective Memory Decline who will progress to mild cognitive impairment or dementia
Subjective memory decline (SMD) is a heterogeneous condition. While SMD might be the earliest sign of Alzheimer’s disease (AD), it also occurs in aging and various neurological, medical, and psychiatric condit...
-
Article
Open AccessInsulin resistance is associated with reductions in specific cognitive domains and increases in CSF tau in cognitively normal adults
Growing evidence supports the hypothesis that type 2 diabetes (T2D) increases the risk of develo** dementia. Experimental evidence from mouse models demonstrates that the induction of T2D/insulin resistance ...
